Peptidomics in drug development:
Saved in:
| Other Authors: | |
|---|---|
| Format: | Book |
| Language: | English |
| Published: |
Aulendorf
Editio-Cantor-Verl.
2005
|
| Subjects: | |
| Online Access: | Inhaltsverzeichnis |
| Physical Description: | 154 S. zahlr. Ill., graph. Darst. |
| ISBN: | 3871933236 |
Staff View
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV021291527 | ||
| 003 | DE-604 | ||
| 005 | 20060719 | ||
| 007 | t | ||
| 008 | 060113s2005 gw ad|| |||| 00||| eng d | ||
| 015 | |a 05,N07,0906 |2 dnb | ||
| 016 | 7 | |a 973512415 |2 DE-101 | |
| 020 | |a 3871933236 |9 3-87193-323-6 | ||
| 024 | 3 | |a 9783871933233 | |
| 035 | |a (OCoLC)68628521 | ||
| 035 | |a (DE-599)BVBBV021291527 | ||
| 040 | |a DE-604 |b ger |e rakddb | ||
| 041 | 0 | |a eng | |
| 044 | |a gw |c XA-DE-BW | ||
| 049 | |a DE-703 |a DE-19 | ||
| 082 | 0 | |a 610 | |
| 084 | |a VS 5350 |0 (DE-625)147687:253 |2 rvk | ||
| 084 | |a VS 9400 |0 (DE-625)147728:253 |2 rvk | ||
| 084 | |a 610 |2 sdnb | ||
| 245 | 1 | 0 | |a Peptidomics in drug development |c edited by Dorothee Gaenshirt ... With contributions from Annette Appel ... |
| 264 | 1 | |a Aulendorf |b Editio-Cantor-Verl. |c 2005 | |
| 300 | |a 154 S. |b zahlr. Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 650 | 4 | |a Biochemical markers |x Therapeutic use | |
| 650 | 4 | |a Biological Markers | |
| 650 | 4 | |a Drug Design | |
| 650 | 4 | |a Drugs |x Design | |
| 650 | 4 | |a Peptides |x Analysis | |
| 650 | 4 | |a Peptides |x Therapeutic use | |
| 650 | 4 | |a Peptides |x genetics | |
| 650 | 0 | 7 | |a Biomarker |0 (DE-588)4425928-1 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Peptidomimetikum |0 (DE-588)4589409-7 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Arzneimittelforschung |0 (DE-588)4003120-2 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Peptidomimetikum |0 (DE-588)4589409-7 |D s |
| 689 | 0 | 1 | |a Arzneimittelforschung |0 (DE-588)4003120-2 |D s |
| 689 | 0 | |5 DE-604 | |
| 689 | 1 | 0 | |a Peptidomimetikum |0 (DE-588)4589409-7 |D s |
| 689 | 1 | 1 | |a Biomarker |0 (DE-588)4425928-1 |D s |
| 689 | 1 | |5 DE-604 | |
| 700 | 1 | |a Ahlert, Dorothee |d 1955- |0 (DE-588)112764959 |4 edt | |
| 700 | 1 | |a Appel, Annette |d 1960- |e Sonstige |0 (DE-588)120044749 |4 oth | |
| 856 | 4 | 2 | |m HBZ Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=014612375&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-014612375 | ||
Record in the Search Index
| _version_ | 1804135084101468160 |
|---|---|
| adam_text | Table of Contents
Introductory Note n
Preface 12
1 The World of Peptidomics 15
1.1 Introduction 15
Peter Schulz Knappe andSven Rohmann
1.2 The Post Genomics Era 16
Peter Schulz Knappe and Michael Schroder
1.3 Peptides of Pharmaceutical Relevance 19
Peter Schulz Knappe
1.3.1 Peptides in biology and medicine 19
1.4 How are Peptides Produced and Processed? 21
Hans Dieter Zucht
1.4.1 Introduction 21
1.4.2 Molecular biology 22
1.4.3 Peptide metabolism and processing 24
1.4.4 The role of peptidases in peptide processing 25
1.4.5 Outlook 28
1.5 General Outline of Peptidomics Technologies 29
Peter Schulz Knappe, HartmutSelle, Hans Dieter Zucht,
and Michael Schroder
1.6 Differential Peptide Display 33
Peter Schulz Knappe, Hans Dieter Zucht, and Michael Schroder
6 Table of Contents
1.7 Bioinformatics and Data Mining 36
Hans Dieter Zucht and Jens Lamerz
1.7.1 The MALDI mass spectrum 36
1.7.2 Data mining 38
1.7.3 First steps in data mining: projection methods 38
1.7.4 Multiple statistical testing procedures 39
1.7.5 Outlook 40
1.8 High throughput Sequence Analysis 41
Markus Kellmann and Christoph Menzel
1.8.1 Introduction 41
1.8.2 Identification workflows 42
1.8.3 Overview identification 43
1.8.4 Biomarker candidate identification 45
1.8.5 Inventory identification 46
1.8.6 Automation of data flow 48
1.8.7 Summary/outlook 49
2 Applications of Peptidomics Technologies 50
2.1 Biomarker Discovery 50
Harald Tammen and Peter Schulz Knappe
2.2 Biomarkers for CNS Diseases 52
HartmutSelle, Hans Dieter Zucht, and Martin U. Schuhmann
2.2.1 Introduction 52
2.2.2 Collection of CSF 53
2.2.3 CSF analysis 53
2.2.4 Peptide analysis for biomarker discovery in CSF 54
2.2.5 Peptide analysis of rodent CSF 57
2.2.6 Summary and conclusion 58
2.3 Analysis of Blood Plasma Peptides 59
Harald Tammen and Rudiger Hess
2.3.1 Introduction 59
2.3.2 Specimen collection 59
2.3.3 Protein depletion and peptide extraction 59
Table of Contents 7
2.4 Peptidomics Based Protease Inhibitor Profiling 65
Marco Jost, Petra Budde, Harald Tammen, and Peter Sehulz Knappe
2.4.1 The peptidome as an in situ library
of protease substrates and products 66
2.4.2 Coagulation 68
2.4.3 Counter regulation of coagulation 68
2.4.4 Experimental design 69
2.4.5 Results 70
2.4.6 DPPIV inhibition 72
2.4.7 DPPIV inhibition induced effects on the blood plasma peptidome 72
2.4.8 Conclusion 73
2.5 Cancer Biomarkers 74
Harald Tammen
2.5.1 Peptidic tumour markers 74
2.5.2 Oncopeptidomics 75
2.6 Characterisation of the Urinary Peptidome 78
Michael Jiirgens, Annette Appel, Susanne Neitz, Gabriele Heine,
and Christoph Menzel
2.6.1 Introduction 78
2.6.2 Biomarker research in urine 78
2.6.3 Methods 78
2.6.4 Results 79
2.6.5 Conclusion 82
2.7 Peptidomics and Diabetes 83
Pefra Budde, Imke Schulte, Hartmut Selle, and Horst Rose
2.7.1 Peptides and the metabolic syndrome 84
2.7.2 Peptides as drugs in pharmaceutical applications 85
2.7.3 Peptidomics for biomarkers and drug discovery 86
2.8 Mouse Models of Obesity and Type 2 Diabetes 90
Petra Budde
2.8.1 Classic mouse and rat models in obesity and diabetes research 90
2.8.2 Differential peptidomics of obesity and diabetes mouse models 90
2.8.3 Obesity and diabetes mouse models in preclinical studies 94
8 Table of Contents
2.9 Profiling of Transcription Modulating Drugs 96
Petra Budde
2.9.1 PPAR and metabolic diseases 97
2.9.2 Expression profiling approaches 99
2.9.3 Peptidomics profiling of TZD responsive small proteins and peptides 101
2.10 Functional Peptidomics 104
Marco Jost, Nicolas Le Yondre, and Rudiger Hess
2.10.1 Introduction 104
2.10.2 Why functional peptidomics? 104
2.10.3 Functional peptidomics using INS 1 cells 105
2.10.4 Conclusion 108
3 The Role of Peptidomics in Drug Development 109
A Global Primary Data Evaluation among REtD Experts
in the Pharmaceutical Industry
Dorothee Gaenshirt and Fred Harms
3.1 Introduction 109
3.1.1 Background 109
3.1.2 Objectives 111
3.2 Methods 112
3.3 Results 112
3.3.1 Responder rate 112
3.3.2 Participants 112
3.3.3 Peptidomics in various areas of drug development 113
3.3.4 Time frames 115
3.3.5 Diagnostics 115
3.3.6 Prediction of therapeutic success 116
3.3.7 Development of lead compounds 116
3.3.8 Additional indications 118
3.3.9 Molecular toxicology 118
3.3.10 Cooperation with biotech companies 119
Table of Contents 9
3.3.11 Nature of collaboration 119
3.3.12 Technology assessment 120
3.3.13 Budget 123
3.4 Conclusion 124
3.4.1 Responder rate 124
3.4.2 Peptidomics in various areas of drug development 125
3.4.3 Peptide therapeutics 125
3.4.4 Biomarkers 126
3.4.5 Indications 127
3.4.6 Collaborative efforts 127
3.4.7 Future challenges 128
3.5 Current Activities and Trends in Commercial Proteomics
and Peptidomics Services 129
Ranald Sutherland
3.5.1 Targeting the need pharmaceutical drug discovery
and development 129
3.5.2 Proteomics services in the drug discovery
and development value chain 130
3.5.3 Trends in pharmaceutical RftD that drive
the proteomics service market 132
4 Outlook 134
Peter Schulz Knappe and Hans DieterZucht
5 References 137
Abbreviations 147
Index 149
Editors CVs 151
The Authors 153
|
| adam_txt |
Table of Contents
Introductory Note n
Preface 12
1 The World of Peptidomics 15
1.1 Introduction 15
Peter Schulz Knappe andSven Rohmann
1.2 The Post Genomics Era 16
Peter Schulz Knappe and Michael Schroder
1.3 Peptides of Pharmaceutical Relevance 19
Peter Schulz Knappe
1.3.1 Peptides in biology and medicine 19
1.4 How are Peptides Produced and Processed? 21
Hans Dieter Zucht
1.4.1 Introduction 21
1.4.2 Molecular biology 22
1.4.3 Peptide metabolism and processing 24
1.4.4 The role of peptidases in peptide processing 25
1.4.5 Outlook 28
1.5 General Outline of Peptidomics Technologies 29
Peter Schulz Knappe, HartmutSelle, Hans Dieter Zucht,
and Michael Schroder
1.6 Differential Peptide Display 33
Peter Schulz Knappe, Hans Dieter Zucht, and Michael Schroder
6 Table of Contents
1.7 Bioinformatics and Data Mining 36
Hans Dieter Zucht and Jens Lamerz
1.7.1 The MALDI mass spectrum 36
1.7.2 Data mining 38
1.7.3 First steps in data mining: projection methods 38
1.7.4 Multiple statistical testing procedures 39
1.7.5 Outlook 40
1.8 High throughput Sequence Analysis 41
Markus Kellmann and Christoph Menzel
1.8.1 Introduction 41
1.8.2 Identification workflows 42
1.8.3 Overview identification 43
1.8.4 Biomarker candidate identification 45
1.8.5 Inventory identification 46
1.8.6 Automation of data flow 48
1.8.7 Summary/outlook 49
2 Applications of Peptidomics Technologies 50
2.1 Biomarker Discovery 50
Harald Tammen and Peter Schulz Knappe
2.2 Biomarkers for CNS Diseases 52
HartmutSelle, Hans Dieter Zucht, and Martin U. Schuhmann
2.2.1 Introduction 52
2.2.2 Collection of CSF 53
2.2.3 CSF analysis 53
2.2.4 Peptide analysis for biomarker discovery in CSF 54
2.2.5 Peptide analysis of rodent CSF 57
2.2.6 Summary and conclusion 58
2.3 Analysis of Blood Plasma Peptides 59
Harald Tammen and Rudiger Hess
2.3.1 Introduction 59
2.3.2 Specimen collection 59
2.3.3 Protein depletion and peptide extraction 59
Table of Contents 7
2.4 Peptidomics Based Protease Inhibitor Profiling 65
Marco Jost, Petra Budde, Harald Tammen, and Peter Sehulz Knappe
2.4.1 The peptidome as an in situ library
of protease substrates and products 66
2.4.2 Coagulation 68
2.4.3 Counter regulation of coagulation 68
2.4.4 Experimental design 69
2.4.5 Results 70
2.4.6 DPPIV inhibition 72
2.4.7 DPPIV inhibition induced effects on the blood plasma peptidome 72
2.4.8 Conclusion 73
2.5 Cancer Biomarkers 74
Harald Tammen
2.5.1 Peptidic tumour markers 74
2.5.2 Oncopeptidomics 75
2.6 Characterisation of the Urinary Peptidome 78
Michael Jiirgens, Annette Appel, Susanne Neitz, Gabriele Heine,
and Christoph Menzel
2.6.1 Introduction 78
2.6.2 Biomarker research in urine 78
2.6.3 Methods 78
2.6.4 Results 79
2.6.5 Conclusion 82
2.7 Peptidomics and Diabetes 83
Pefra Budde, Imke Schulte, Hartmut Selle, and Horst Rose
2.7.1 Peptides and the metabolic syndrome 84
2.7.2 Peptides as drugs in pharmaceutical applications 85
2.7.3 Peptidomics for biomarkers and drug discovery 86
2.8 Mouse Models of Obesity and Type 2 Diabetes 90
Petra Budde
2.8.1 Classic mouse and rat models in obesity and diabetes research 90
2.8.2 Differential peptidomics of obesity and diabetes mouse models 90
2.8.3 Obesity and diabetes mouse models in preclinical studies 94
8 Table of Contents
2.9 Profiling of Transcription Modulating Drugs 96
Petra Budde
2.9.1 PPAR and metabolic diseases 97
2.9.2 Expression profiling approaches 99
2.9.3 Peptidomics profiling of TZD responsive small proteins and peptides 101
2.10 Functional Peptidomics 104
Marco Jost, Nicolas Le Yondre, and Rudiger Hess
2.10.1 Introduction 104
2.10.2 Why functional peptidomics? 104
2.10.3 Functional peptidomics using INS 1 cells 105
2.10.4 Conclusion 108
3 The Role of Peptidomics in Drug Development 109
A Global Primary Data Evaluation among REtD Experts
in the Pharmaceutical Industry
Dorothee Gaenshirt and Fred Harms
3.1 Introduction 109
3.1.1 Background 109
3.1.2 Objectives 111
3.2 Methods 112
3.3 Results 112
3.3.1 Responder rate 112
3.3.2 Participants 112
3.3.3 Peptidomics in various areas of drug development 113
3.3.4 Time frames 115
3.3.5 Diagnostics 115
3.3.6 Prediction of therapeutic success 116
3.3.7 Development of lead compounds 116
3.3.8 Additional indications 118
3.3.9 Molecular toxicology 118
3.3.10 Cooperation with biotech companies 119
Table of Contents 9
3.3.11 Nature of collaboration 119
3.3.12 Technology assessment 120
3.3.13 Budget 123
3.4 Conclusion 124
3.4.1 Responder rate 124
3.4.2 Peptidomics in various areas of drug development 125
3.4.3 Peptide therapeutics 125
3.4.4 Biomarkers 126
3.4.5 Indications 127
3.4.6 Collaborative efforts 127
3.4.7 Future challenges 128
3.5 Current Activities and Trends in Commercial Proteomics
and Peptidomics Services 129
Ranald Sutherland
3.5.1 Targeting the need pharmaceutical drug discovery
and development 129
3.5.2 Proteomics services in the drug discovery
and development value chain 130
3.5.3 Trends in pharmaceutical RftD that drive
the proteomics service market 132
4 Outlook 134
Peter Schulz Knappe and Hans DieterZucht
5 References 137
Abbreviations 147
Index 149
Editors'CVs 151
The Authors 153 |
| any_adam_object | 1 |
| any_adam_object_boolean | 1 |
| author2 | Ahlert, Dorothee 1955- |
| author2_role | edt |
| author2_variant | d a da |
| author_GND | (DE-588)112764959 (DE-588)120044749 |
| author_facet | Ahlert, Dorothee 1955- |
| building | Verbundindex |
| bvnumber | BV021291527 |
| classification_rvk | VS 5350 VS 9400 |
| ctrlnum | (OCoLC)68628521 (DE-599)BVBBV021291527 |
| dewey-full | 610 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 610 - Medicine and health |
| dewey-raw | 610 |
| dewey-search | 610 |
| dewey-sort | 3610 |
| dewey-tens | 610 - Medicine and health |
| discipline | Chemie / Pharmazie Medizin |
| discipline_str_mv | Chemie / Pharmazie Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02172nam a2200577 c 4500</leader><controlfield tag="001">BV021291527</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20060719 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">060113s2005 gw ad|| |||| 00||| eng d</controlfield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">05,N07,0906</subfield><subfield code="2">dnb</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">973512415</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3871933236</subfield><subfield code="9">3-87193-323-6</subfield></datafield><datafield tag="024" ind1="3" ind2=" "><subfield code="a">9783871933233</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)68628521</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV021291527</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakddb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">gw</subfield><subfield code="c">XA-DE-BW</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-703</subfield><subfield code="a">DE-19</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">VS 5350</subfield><subfield code="0">(DE-625)147687:253</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">VS 9400</subfield><subfield code="0">(DE-625)147728:253</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">610</subfield><subfield code="2">sdnb</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Peptidomics in drug development</subfield><subfield code="c">edited by Dorothee Gaenshirt ... With contributions from Annette Appel ...</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Aulendorf</subfield><subfield code="b">Editio-Cantor-Verl.</subfield><subfield code="c">2005</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">154 S.</subfield><subfield code="b">zahlr. Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Biochemical markers</subfield><subfield code="x">Therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Biological Markers</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Design</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drugs</subfield><subfield code="x">Design</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Peptides</subfield><subfield code="x">Analysis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Peptides</subfield><subfield code="x">Therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Peptides</subfield><subfield code="x">genetics</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Biomarker</subfield><subfield code="0">(DE-588)4425928-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Peptidomimetikum</subfield><subfield code="0">(DE-588)4589409-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittelforschung</subfield><subfield code="0">(DE-588)4003120-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Peptidomimetikum</subfield><subfield code="0">(DE-588)4589409-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Arzneimittelforschung</subfield><subfield code="0">(DE-588)4003120-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Peptidomimetikum</subfield><subfield code="0">(DE-588)4589409-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Biomarker</subfield><subfield code="0">(DE-588)4425928-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ahlert, Dorothee</subfield><subfield code="d">1955-</subfield><subfield code="0">(DE-588)112764959</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Appel, Annette</subfield><subfield code="d">1960-</subfield><subfield code="e">Sonstige</subfield><subfield code="0">(DE-588)120044749</subfield><subfield code="4">oth</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=014612375&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-014612375</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV021291527 |
| illustrated | Illustrated |
| index_date | 2024-07-02T13:49:57Z |
| indexdate | 2024-07-09T20:34:52Z |
| institution | BVB |
| isbn | 3871933236 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-014612375 |
| oclc_num | 68628521 |
| open_access_boolean | |
| owner | DE-703 DE-19 DE-BY-UBM |
| owner_facet | DE-703 DE-19 DE-BY-UBM |
| physical | 154 S. zahlr. Ill., graph. Darst. |
| publishDate | 2005 |
| publishDateSearch | 2005 |
| publishDateSort | 2005 |
| publisher | Editio-Cantor-Verl. |
| record_format | marc |
| spelling | Peptidomics in drug development edited by Dorothee Gaenshirt ... With contributions from Annette Appel ... Aulendorf Editio-Cantor-Verl. 2005 154 S. zahlr. Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Biochemical markers Therapeutic use Biological Markers Drug Design Drugs Design Peptides Analysis Peptides Therapeutic use Peptides genetics Biomarker (DE-588)4425928-1 gnd rswk-swf Peptidomimetikum (DE-588)4589409-7 gnd rswk-swf Arzneimittelforschung (DE-588)4003120-2 gnd rswk-swf (DE-588)4143413-4 Aufsatzsammlung gnd-content Peptidomimetikum (DE-588)4589409-7 s Arzneimittelforschung (DE-588)4003120-2 s DE-604 Biomarker (DE-588)4425928-1 s Ahlert, Dorothee 1955- (DE-588)112764959 edt Appel, Annette 1960- Sonstige (DE-588)120044749 oth HBZ Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=014612375&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Peptidomics in drug development Biochemical markers Therapeutic use Biological Markers Drug Design Drugs Design Peptides Analysis Peptides Therapeutic use Peptides genetics Biomarker (DE-588)4425928-1 gnd Peptidomimetikum (DE-588)4589409-7 gnd Arzneimittelforschung (DE-588)4003120-2 gnd |
| subject_GND | (DE-588)4425928-1 (DE-588)4589409-7 (DE-588)4003120-2 (DE-588)4143413-4 |
| title | Peptidomics in drug development |
| title_auth | Peptidomics in drug development |
| title_exact_search | Peptidomics in drug development |
| title_exact_search_txtP | Peptidomics in drug development |
| title_full | Peptidomics in drug development edited by Dorothee Gaenshirt ... With contributions from Annette Appel ... |
| title_fullStr | Peptidomics in drug development edited by Dorothee Gaenshirt ... With contributions from Annette Appel ... |
| title_full_unstemmed | Peptidomics in drug development edited by Dorothee Gaenshirt ... With contributions from Annette Appel ... |
| title_short | Peptidomics in drug development |
| title_sort | peptidomics in drug development |
| topic | Biochemical markers Therapeutic use Biological Markers Drug Design Drugs Design Peptides Analysis Peptides Therapeutic use Peptides genetics Biomarker (DE-588)4425928-1 gnd Peptidomimetikum (DE-588)4589409-7 gnd Arzneimittelforschung (DE-588)4003120-2 gnd |
| topic_facet | Biochemical markers Therapeutic use Biological Markers Drug Design Drugs Design Peptides Analysis Peptides Therapeutic use Peptides genetics Biomarker Peptidomimetikum Arzneimittelforschung Aufsatzsammlung |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=014612375&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT ahlertdorothee peptidomicsindrugdevelopment AT appelannette peptidomicsindrugdevelopment |